Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PSA Clear all
Active, not recruiting Phase 2 Interventional Results available

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

NCT03600350
View directory record Official record
Conditions
Prostate Cancer
Interventions
pTVG-HP, Nivolumab, GM-CSF
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Docetaxel, TroVax
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Results available

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 8:12 PM EDT
Not listed No phase listed Observational

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

NCT05925842
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Network
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

NCT02673151
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial

NCT00630188
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
You Decide, Reducing Your Risks in the Crash
Other
Lead sponsor
University of North Carolina
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1

NCT01241656
View directory record Official record
Conditions
Healthy Men Age 50 Who Are Considering PSA Screening
Interventions
DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
2,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Palo Alto, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Jul 22, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

NCT00005039
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jul 22, 2026, 8:12 PM EDT
Completed No phase listed Observational

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

NCT02413749
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 22, 2026, 8:12 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Prostate Cancer Genius App Education and Home-based PSA Screening for African American Men

NCT05331638
View directory record Official record
Conditions
Prostate Cancer, Health Behavior
Interventions
Prostate Cancer Genius App, US Prevention Taskforce App
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 69 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 8:12 PM EDT
Terminated Not applicable Interventional

Pilot Study of a Catheter-based Ultrasound Hyperthermia System

NCT00911079
View directory record Official record
Conditions
Cervical Cancer, Prostate Cancer
Interventions
Hyperthermia, HDR brachytherapy
Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 22, 2026, 8:12 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis

NCT05195814
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Green Tea Extract and Prostate Cancer

NCT00676780
View directory record Official record
Conditions
Prostate Cancer
Interventions
Polyphenon E (EGCG)
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

NCT02319759
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 8:12 PM EDT
Enrolling by invitation Not applicable Interventional

Fusion Guided Focal Laser Ablation of Prostate Cancer

NCT02759744
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasms
Interventions
ultrasound image-guided ablation device
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

NCT00450463
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jul 22, 2026, 8:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

NCT03809000
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog
Radiation · Drug
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
106
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 22, 2026, 8:12 PM EDT
Recruiting No phase listed Observational

MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer

NCT05241236
View directory record Official record
Conditions
Neoplasms Prostate, Cancer of the Prostate
Interventions
Image Fusion (MR/US) Software Registration Guided Laser Ablation of Prostate Cancer
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
50 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

NCT02796898
View directory record Official record
Conditions
Prostate Cancer, Rising Prostate Specific Antigen (PSA)
Interventions
SM88 (Cohort 1), SM88 (Cohort 2)
Drug
Lead sponsor
Tyme, Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Lawrence, New Jersey • Garden City, New York • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Jul 22, 2026, 8:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

NCT00861471
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Jul 22, 2026, 8:12 PM EDT
Recruiting Not applicable Interventional

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT04692675
View directory record Official record
Conditions
Prostate Cancer
Interventions
mpMRI
Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 8:12 PM EDT
Completed Not applicable Interventional

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications

NCT04081636
View directory record Official record
Conditions
Prostate Cancer, PSA, Infection
Interventions
Systematic Transrectal biopsy (TR-Bx), Targeted Transrectal biopsy (TR-Bx), Systematic Transperineal biopsy (TP-Bx), Targeted Transperineal biopsy (TP-Bx)
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
Male only
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 8:12 PM EDT
Terminated Phase 2 Interventional Results available

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

NCT03042312
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
177Lu-PSMA-617
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 8:12 PM EDT